ASTRAZENECA PLC DL-,25/ GB0009895292 /
2024-04-19 2:27:16 PM | Chg. -0.450 | Volume | Bid2:27:16 PM | Ask2:27:16 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
127.600EUR | -0.35% | - Turnover: - |
127.600Bid Size: - | 127.700Ask Size: - | 196.51 bill.EUR | - | - |
GlobeNewswire
03-28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
GlobeNewswire
02-26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
02-05
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, an...
GlobeNewswire
02-02
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patie...
GlobeNewswire
01-03
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Li...
GlobeNewswire
2023-12-26
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncol...
GlobeNewswire
2023-12-22
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023